TACR1 and leukemia: After treatment with NK-1R antagonists, a cell cycle arrest was observed in leukemia cells: a cell increase in G0/G1 phase was reported, as well as a significant decrease of cells in S phase, whereas the expression levels of CDC25A, CDK4, cyclin B1 and cyclin D1 were decreased and those of CDK inhibitors p16 and p21 were increased (Table 2) [1].